Clinical trial
A Multinational Randomized Double-Blind Placebo-Controlled Phase 2 Study to Evaluate the Effect of Linvemastat (FP-020) in Patients With Partially Controlled Asthma on Inhaled Corticosteroids and Long-Acting Beta-Agonists (syMMPonia Study)
NCT07191535 is registered in ClinicalTrials.gov with Foresee Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multinational Randomized Double-Blind Placebo-Controlled Phase 2 Study to Evaluate the Effect of Linvemastat (FP-020) in Patients With Partially Controlled Asthma on Inhaled Corticosteroids and Long-Acting Beta-Agonists (syMMPonia Study)
- Lead sponsor
- Foresee Pharmaceuticals Co., Ltd.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 1, 2027
- Completion date
- September 1, 2028
- Enrollment
- 135 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
asthma (diagnosis), moderate-to-severe asthma, pulmonary function